Viatris Inc. Common Stock

VTRS

Viatris Inc. (VTRS) is a global healthcare company formed through the merger of Mylan and Pfizer’s Upjohn unit. The company specializes in developing, manufacturing, and marketing a broad range of pharmaceuticals, including generic, branded, and biosimilar medicines, with a focus on improving access to affordable healthcare worldwide.

$10.19 +0.01 (0.10%)
Dividend Yield 4.71%
Payout Frequency Quarterly

Dividend History

🎉 Upcoming Dividend

Investors can expect a dividend payout of $0.12 per share, scheduled to be distributed in 24 days on December 15, 2025

Pay DateAmountEx-DateRecord Date
December 15, 2025$0.122025-11-242025-11-24
September 15, 2025$0.122025-08-222025-08-22
June 16, 2025$0.122025-05-232025-05-23
March 18, 2025$0.122025-03-102025-03-10
December 13, 2024$0.122024-11-222024-11-22

Dividends Summary

Company News

What Occidental Petroleum’s Latest Backer Sees in Oil’s Next Chapter
The Motley Fool • Eric Trie • October 25, 2025

QSM Asset Management initiated a new $10.31 million position in Occidental Petroleum, acquiring 221,760 shares in Q3 2025, despite the stock's 18.77% decline over the past year.

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
Benzinga • Vandana Singh • October 9, 2025

The Trump administration will exclude imported generic drugs from potential tariffs, bringing relief to pharmaceutical companies and Indian drugmakers who supply nearly half of U.S. generic prescriptions.

Epinephrine Market to Size to Reach USD 5.74 Billion by 2032 as Demand for Emergency Allergy Treatments Surges – SNS Insider
GlobeNewswire Inc. • Sns Insider • September 1, 2025

The global epinephrine market is projected to grow from $2.77 billion in 2024 to $5.74 billion by 2032, driven by increasing cases of severe allergic reactions, technological advancements in auto-injectors, and rising awareness of anaphylaxis risks.

S&P 500 Four Under Five
Seeking Alpha • Bespoke Investment Group • June 30, 2024

Four stocks in the S&P 500 have a lower earnings multiple than the 4.9 percentage point gap between the average and median multiple of the index’s components. Click to read more.

Here's Why You May Invest in Theravance (TBPH) Stock Now
Zacks Investment Research • Zacks Equity Research • June 26, 2024

Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.

Related Companies